These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 943370)

  • 1. Interaction of properdin convertase and properdin in the alternative pathway of complement activation.
    Spitzer RE; Stitzel AE; Urmson J
    Immunochemistry; 1976 Jan; 13(1):15-20. PubMed ID: 943370
    [No Abstract]   [Full Text] [Related]  

  • 2. The utilization of properdin in the alternate pathway of complement activation: isolation of properdin convertase.
    Stitzel AE; Spitzer RE
    J Immunol; 1974 Jan; 112(1):56-62. PubMed ID: 4130153
    [No Abstract]   [Full Text] [Related]  

  • 3. The binding of human complement proteins C5, factor B, beta 1H and properdin to complement fragment C3b on zymosan.
    DiScipio RG
    Biochem J; 1981 Dec; 199(3):485-96. PubMed ID: 6462133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Pangburn MK; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
    Whaley K; Schur PH; Ruddy S
    J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
    Medicus RG; Götze O; Müller-Eberhard HJ
    J Exp Med; 1976 Oct; 144(4):1076-93. PubMed ID: 978134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.
    Schreiber RD; Götze O; Müller-Eberhard HJ
    J Exp Med; 1976 Oct; 144(4):1062-75. PubMed ID: 62010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of factor B and C3 in guinea pig serum by zymosan or by activated properdin depends on the presence of factor D.
    Brade V; Bentley C; Kossorotow A; Bitter-Suermann D
    Monogr Allergy; 1977; 12():83-5. PubMed ID: 917024
    [No Abstract]   [Full Text] [Related]  

  • 9. Activation of the alternative pathway of complement in childhood acute lymphoblastic leukemia.
    Kalwinsky DK; Urmson JR; Stitzel AE; Spitzer RE
    J Lab Clin Med; 1976 Nov; 88(5):745-56. PubMed ID: 1068203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel mechanism of complement inhibition unmasked by a tick salivary protein that binds to properdin.
    Tyson KR; Elkins C; de Silva AM
    J Immunol; 2008 Mar; 180(6):3964-8. PubMed ID: 18322205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The alternative pathway of complement activation.
    Götze O; Müller-Eberhard HJ
    Adv Immunol; 1976; 24():1-35. PubMed ID: 798473
    [No Abstract]   [Full Text] [Related]  

  • 13. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.
    Fearon DT; Austen KF
    Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1683-7. PubMed ID: 266208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.
    Fearon DT; Austen KF
    J Exp Med; 1975 Oct; 142(4):856-63. PubMed ID: 1185108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivator of the third component of complement as an inhibitor in the properdin pathway.
    Alper CA; Rosen FS; Lachmann PJ
    Proc Natl Acad Sci U S A; 1972 Oct; 69(10):2910-3. PubMed ID: 4507613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The multifunctional role of C3: structural analysis of its interactions with physiological ligands.
    Lambris JD; Müller-Eberhard HJ
    Mol Immunol; 1986 Nov; 23(11):1237-42. PubMed ID: 2950317
    [No Abstract]   [Full Text] [Related]  

  • 17. Association of activated properdin with complexes of properdin with C3.
    Whiteman LY; Purkall DB; Ruddy S
    J Immunol; 1991 Aug; 147(4):1344-51. PubMed ID: 1869827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
    Vogt W; Schmidt G; Lynen R; Dieminger L
    J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A molecular concept of the properdin pathway.
    Medicus RG; Schreiber RD; Götze O; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1976 Feb; 73(2):612-6. PubMed ID: 54923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Properdin factor D. II. Activation to D by properdin.
    Fearon DT; Austen KF; Ruddy S
    J Exp Med; 1974 Aug; 140(2):426-36. PubMed ID: 4211020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.